NCT04939116

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Safety and Efficacy of ANG-3070 in Patients With Primary Glomerular Disease and Persistent Proteinuria

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Angion Biomedica Corp · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.

Detailed description

To evaluate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria while on the SOC, as measured by a reduction in the 24-hour urinary protein excretion.

Conditions

• Glomerular Disease
• Proteinuria

Interventions

Type	Name	Description
DRUG	ANG-3070	Orally administered tyrosine kinase inhibitor capsule
DRUG	Placebo	Orally administered placebo capsule

Timeline

• Start date: 2021-12-24
• Primary completion: 2023-07-31
• Completion: 2023-08-31
• First posted: 2021-06-25
• Last updated: 2022-03-23

Locations

30 sites across 3 countries: United States, Australia, Georgia

Regulatory

• FDA-regulated drug study